1
|
Billard E, Létourneau M, Hébert TE, Chatenet D. Insight into the role of urotensin II-related peptide tyrosine residue in UT activation. Biochem Pharmacol 2017; 144:100-107. [DOI: 10.1016/j.bcp.2017.08.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2017] [Accepted: 08/03/2017] [Indexed: 12/16/2022]
|
2
|
Synthetic Peptide Analogs of Somatostatin: Trends in the Synthesis of and Prospects in the Search for New Anticancer Drugs. Pharm Chem J 2015. [DOI: 10.1007/s11094-015-1284-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
3
|
Stengel A, Karasawa H, Taché Y. The role of brain somatostatin receptor 2 in the regulation of feeding and drinking behavior. Horm Behav 2015; 73:15-22. [PMID: 26026616 PMCID: PMC4546908 DOI: 10.1016/j.yhbeh.2015.05.009] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2015] [Revised: 05/13/2015] [Accepted: 05/18/2015] [Indexed: 12/13/2022]
Abstract
Somatostatin was discovered four decades ago as hypothalamic factor inhibiting growth hormone release. Subsequently, somatostatin was found to be widely distributed throughout the brain and to exert pleiotropic actions via interaction with five somatostatin receptors (sst1-5) that are also widely expressed throughout the brain. Interestingly, in contrast to the predominantly inhibitory actions of peripheral somatostatin, the activation of brain sst2 signaling by intracerebroventricular injection of stable somatostatin agonists potently stimulates food intake and independently, drinking behavior in rodents. The orexigenic response involves downstream orexin-1, neuropeptide Y1 and μ receptor signaling while the dipsogenic effect is mediated through the activation of the brain angiotensin 1 receptor. Brain sst2 activation is part of mechanisms underlying the stimulation of feeding and more prominently water intake in the dark phase and is able to counteract the anorexic response to visceral stressors.
Collapse
Affiliation(s)
- Andreas Stengel
- Charité Center for Internal Medicine and Dermatology, Division of General Internal and Psychosomatic Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
| | - Hiroshi Karasawa
- CURE: Digestive Diseases Research Center, Center for Neurobiology of Stress and Women's Health, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| | - Yvette Taché
- CURE: Digestive Diseases Research Center, Center for Neurobiology of Stress and Women's Health, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA.
| |
Collapse
|
4
|
Kolenc Peitl P, Tamma M, Kroselj M, Braun F, Waser B, Reubi JC, Sollner Dolenc M, Maecke HR, Mansi R. Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor. Bioconjug Chem 2015; 26:1113-9. [PMID: 25971921 DOI: 10.1021/acs.bioconjchem.5b00187] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The metabolic instability and high kidney retention of minigastrin (MG) analogues hamper their suitability for use in peptide-receptor radionuclide therapy of CCK2/gastrin receptor-expressing tumors. High kidney retention has been related to N-terminal glutamic acids and can be substantially reduced by coinjection of polyglutamic acids or gelofusine. The aim of the present study was to investigate the influence of the stereochemistry of the N-terminal amino acid spacer on the enzymatic stability and pharmacokinetics of (111)In-DOTA-(d-Glu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 ((111)In-PP11-D) and (111)In-DOTA-(l-Glu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 ((111)In-PP11-L). Using circular dichroism measurements, we demonstrate the important role of secondary structure on the pharmacokinetics of the two MG analogues. The higher in vitro serum stability together with the improved tumor-to-kidney ratio of the (d-Glu)6 congener indicates that this MG analogue might be a good candidate for further clinical study.
Collapse
Affiliation(s)
- Petra Kolenc Peitl
- †Department of Nuclear Medicine, University Medical Centre Ljubljana, Zaloska cesta 7, SI-1000 Ljubljana, Slovenia
| | - MariaLuisa Tamma
- ‡Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland
| | - Marko Kroselj
- †Department of Nuclear Medicine, University Medical Centre Ljubljana, Zaloska cesta 7, SI-1000 Ljubljana, Slovenia
| | - Friederike Braun
- §Department of Nuclear Medicine, University of Freiburg, Hugstetterstrasse 55, 79106 Freiburg, Germany
| | - Beatrice Waser
- ∥Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Murtenstrasse 31, CH-3010 Berne, Switzerland
| | - Jean Claude Reubi
- ∥Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Murtenstrasse 31, CH-3010 Berne, Switzerland
| | - Marija Sollner Dolenc
- ⊥Faculty of Pharmacy, University of Ljubljana, Askerceva cesta 7, SI-1000 Ljubljana, Slovenia
| | - Helmut R Maecke
- ‡Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.,§Department of Nuclear Medicine, University of Freiburg, Hugstetterstrasse 55, 79106 Freiburg, Germany
| | - Rosalba Mansi
- ‡Division of Radiological Chemistry, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland.,§Department of Nuclear Medicine, University of Freiburg, Hugstetterstrasse 55, 79106 Freiburg, Germany
| |
Collapse
|
5
|
Mulak A, Larauche M, Biraud M, Million M, Rivier J, Taché Y. Selective agonists of somatostatin receptor subtype 1 or 2 injected peripherally induce antihyperalgesic effect in two models of visceral hypersensitivity in mice. Peptides 2015; 63:71-80. [PMID: 25451334 PMCID: PMC4385413 DOI: 10.1016/j.peptides.2014.10.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/13/2014] [Revised: 10/27/2014] [Accepted: 10/28/2014] [Indexed: 02/08/2023]
Abstract
Somatostatin interacts with five G-protein-coupled receptor (sst1-5). Octreotide, a stable sst2≫3≥5 agonist, exerts a visceral anti-hyperalgesic effect in experimental and clinical studies. Little is known on the receptor subtypes involved. We investigated the influence of the stable sst1-5 agonist, ODT8-SST and selective receptor subtype peptide agonists (3 or 10μg/mouse) injected intraperitoneally (ip) on visceral hypersensitivity in mice induced by repeated noxious colorectal distensions (four sets of three CRD, each at 55mmHg) or corticotropin-releasing factor receptor 1 agonist, cortagine given between two sets of graded CRD (15, 30, 45, and 60mmHg, three times each pressure). The mean visceromotor response (VMR) was assessed using a non-invasive manometry method and values were expressed as percentage of the VMR to the 1st set of CRD baseline or to the 60mmHg CRD, respectively. ODT8-SST (10μg) and the sst2 agonist, S-346-011 (3 and 10μg) prevented mechanically induced visceral hypersensitivity in the three sets of CRD, the sst1 agonist (10μg) blocked only the 2nd set and showed a trend at 3μg while the sst4 agonist had no effect. The selective sst2 antagonist, S-406-028 blocked the sst2 agonist but not the sst1 agonist effect. The sst1 agonist (3 and 10μg) prevented cortagine-induced hypersensitivity to CRD at each pressure while the sst2 agonist at 10μg reduced it. These data indicate that in addition to sst2, the sst1 agonist may provide a novel promising target to alleviate visceral hypersensitivity induced by mechanoreceptor sensitization and more prominently, stress-related visceral nociceptive sensitization.
Collapse
Affiliation(s)
- Agata Mulak
- Department of Medicine, CURE: Digestive Diseases Research Center and Oppenheimer Family Center for Neurobiology of Stress, Digestive Diseases Division at the University of California Los Angeles and VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA; Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland
| | - Muriel Larauche
- Department of Medicine, CURE: Digestive Diseases Research Center and Oppenheimer Family Center for Neurobiology of Stress, Digestive Diseases Division at the University of California Los Angeles and VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
| | - Mandy Biraud
- Department of Medicine, CURE: Digestive Diseases Research Center and Oppenheimer Family Center for Neurobiology of Stress, Digestive Diseases Division at the University of California Los Angeles and VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
| | - Mulugeta Million
- Department of Medicine, CURE: Digestive Diseases Research Center and Oppenheimer Family Center for Neurobiology of Stress, Digestive Diseases Division at the University of California Los Angeles and VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
| | - Jean Rivier
- The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, CA, USA
| | - Yvette Taché
- Department of Medicine, CURE: Digestive Diseases Research Center and Oppenheimer Family Center for Neurobiology of Stress, Digestive Diseases Division at the University of California Los Angeles and VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
| |
Collapse
|
6
|
Maina T, Cescato R, Waser B, Tatsi A, Kaloudi A, Krenning EP, de Jong M, Nock BA, Reubi JC. [111In-DOTA]LTT-SS28, a First Pansomatostatin Radioligand for in Vivo Targeting of Somatostatin Receptor-Positive Tumors. J Med Chem 2014; 57:6564-71. [DOI: 10.1021/jm500581d] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Affiliation(s)
- Theodosia Maina
- Molecular
Radiopharmacy, INRASTES, National Center for Scientific Research “Demokritos”, GR-153 10 Athens, Greece
| | - Renzo Cescato
- Cell
Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland
| | - Beatrice Waser
- Cell
Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland
| | - Aikaterini Tatsi
- Molecular
Radiopharmacy, INRASTES, National Center for Scientific Research “Demokritos”, GR-153 10 Athens, Greece
| | - Aikaterini Kaloudi
- Molecular
Radiopharmacy, INRASTES, National Center for Scientific Research “Demokritos”, GR-153 10 Athens, Greece
| | - Eric P. Krenning
- Department
of Nuclear Medicine, Erasmus MC, 3015 CE Rotterdam, The Netherlands
| | - Marion de Jong
- Department
of Nuclear Medicine, Erasmus MC, 3015 CE Rotterdam, The Netherlands
- Department
of Radiology, Erasmus MC, 3015 CE Rotterdam, The Netherlands
| | - Berthold A. Nock
- Molecular
Radiopharmacy, INRASTES, National Center for Scientific Research “Demokritos”, GR-153 10 Athens, Greece
| | - Jean Claude Reubi
- Cell
Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland
| |
Collapse
|
7
|
Karasawa H, Yakabi S, Wang L, Stengel A, Rivier J, Taché Y. Brain somatostatin receptor 2 mediates the dipsogenic effect of central somatostatin and cortistatin in rats: role in drinking behavior. Am J Physiol Regul Integr Comp Physiol 2014; 307:R793-801. [PMID: 25031229 DOI: 10.1152/ajpregu.00248.2014] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Intracerebroventricular injection of stable somatostatin (SST) agonists stimulates food and water intake in rats. We investigated the receptor subtype(s) involved in the dipsogenic effect of intracerebroventricular injection of SST agonists, mechanisms of action, and role. In nonfasted and non-water-deprived male rats with chronic intracerebroventricular cannula, intake of water without food or food without water was monitored separately to avoid any interactions compared with intracerebroventricular vehicle. SST-14 and cortistatin (CST-14) (1 μg/rat icv) increased water intake by 3.1- and 2.7-fold, respectively, while both peptides did not alter food intake at 1 h postinjection in the light phase. By contrast, the stable pan-somatostatin agonist ODT8-SST (1 μg/rat icv) increased both water and food intake by 4.9- and 3.7-fold, respectively. S-346-011, a selective receptor 2 (sst2) agonist (1 μg/rat icv) induced water ingestion, while sst1 or sst4 agonist, injected under the same conditions, did not. The sst2 antagonist S-406-028 (1 μg/rat icv) prevented the 1-h water intake induced by intracerebroventricular ODT8-SST and CST-14. Losartan (100 μg/rat icv), an angiotensin receptor 1 (AT1) antagonist, completely blocked the water consumption induced by intracerebroventricular ODT8-SST, whereas intracerebroventricular injection of S-406-028 did not modify the intracerebroventricular ANG II-induced dipsogenic response. The sst2 antagonist reduced by 40% the increase of the 3-h water intake in the early dark phase. These data indicate that SST-14 and CST-14 interact with sst2 to exert a potent dipsogenic effect, which is mediated downstream by angiotensin-AT1 signaling. These data also indicate that sst2 activation by brain SST-14 and/or CST-14 may play an important role in the regulation of drinking behavior.
Collapse
Affiliation(s)
- Hiroshi Karasawa
- Department of Medicine, CURE/Digestive Diseases Center, Digestive Diseases Division, University of California at Los Angeles, and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; and
| | - Seiichi Yakabi
- Department of Medicine, CURE/Digestive Diseases Center, Digestive Diseases Division, University of California at Los Angeles, and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; and
| | - Lixin Wang
- Department of Medicine, CURE/Digestive Diseases Center, Digestive Diseases Division, University of California at Los Angeles, and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; and
| | - Andreas Stengel
- Department of Medicine, CURE/Digestive Diseases Center, Digestive Diseases Division, University of California at Los Angeles, and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; and
| | - Jean Rivier
- The Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, California
| | - Yvette Taché
- Department of Medicine, CURE/Digestive Diseases Center, Digestive Diseases Division, University of California at Los Angeles, and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California; and
| |
Collapse
|
8
|
Martín-Gago P, Ramón R, Aragón E, Fernández-Carneado J, Martin-Malpartida P, Verdaguer X, López-Ruiz P, Colás B, Cortes MA, Ponsati B, Macias MJ, Riera A. A tetradecapeptide somatostatin dicarba-analog: Synthesis, structural impact and biological activity. Bioorg Med Chem Lett 2014; 24:103-7. [DOI: 10.1016/j.bmcl.2013.11.065] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Revised: 11/21/2013] [Accepted: 11/25/2013] [Indexed: 01/19/2023]
|
9
|
Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting. Eur J Med Chem 2013; 73:30-7. [PMID: 24378707 DOI: 10.1016/j.ejmech.2013.12.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2013] [Revised: 11/27/2013] [Accepted: 12/08/2013] [Indexed: 12/23/2022]
Abstract
Multiple somatostatin receptor (sst)-subtype expression has been manifested in several human tumors. Hence, the availability of radiopeptides retaining the full pansomatostatin profile of the native hormone (SS14) is expected to increase the sensitivity and broaden the clinical indications of currently applied sst2-preferring cyclic octapeptide radioligands, like OctreoScan(®) ([(111)In-DTPA]octreotide). On the other hand, SS14 has been excluded from clinical use due to its rapid in vivo degradation. We herein present a small library of seven novel cyclic SS14-mimics carrying at their N-terminus the universal chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) for stable binding of medically useful radiometals, like (111)In. By decreasing the number of amino acids composing the ring in their structure from 12 up to 6 AA, we induced important changes in key-biological parameters in vitro and in vivo. In particular, we observed unexpected changes and even total loss of sst1-5-affinity (6AA-ring), as well as weaker sst2-internalization efficacy as the ring size decreased. In contrast, in vivo stability increased with decreasing ring size, reaching its maximum in the 6AA-ring analogs. Interestingly, only the 12AA- and 9AA-ring members of this series showed sst2-specific uptake in AR4-2J tumors in mice revealing the prominent role of ring size on the biological response of tested SS14-derived radioligands.
Collapse
Affiliation(s)
- Aikaterini Tatsi
- Molecular Radiopharmacy, INRASTES, NCSR "Demokritos", Ag. Paraskevi Attikis, GR-153 10 Athens, Greece; Department of Radiology, Erasmus MC, 3015 GD, Rotterdam, The Netherlands
| | - Theodosia Maina
- Molecular Radiopharmacy, INRASTES, NCSR "Demokritos", Ag. Paraskevi Attikis, GR-153 10 Athens, Greece
| | - Renzo Cescato
- Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland
| | - Beatrice Waser
- Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland
| | - Eric P Krenning
- Department of Nuclear Medicine, Erasmus MC, 3015 GD, Rotterdam, The Netherlands
| | - Marion de Jong
- Department of Nuclear Medicine, Erasmus MC, 3015 GD, Rotterdam, The Netherlands; Department of Radiology, Erasmus MC, 3015 GD, Rotterdam, The Netherlands
| | - Paul Cordopatis
- Department of Pharmacy, University of Patras, GR-26500 Patras, Greece
| | - Jean-Claude Reubi
- Institute of Pathology, University of Berne, CH-3010 Berne, Switzerland
| | - Berthold A Nock
- Molecular Radiopharmacy, INRASTES, NCSR "Demokritos", Ag. Paraskevi Attikis, GR-153 10 Athens, Greece.
| |
Collapse
|
10
|
Chatenet D, Folch B, Feytens D, Létourneau M, Tourwé D, Doucet N, Fournier A. Development and Pharmacological Characterization of Conformationally Constrained Urotensin II-Related Peptide Agonists. J Med Chem 2013; 56:9612-22. [DOI: 10.1021/jm401153j] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- David Chatenet
- INRS-Institut
Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Ville de Laval, Québec, QC H7V 1B7, Canada
- Laboratoire International
Associé Samuel de Champlain, INSERM-INRS-Université
de Rouen
| | - Benjamin Folch
- INRS-Institut
Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Ville de Laval, Québec, QC H7V 1B7, Canada
| | - Debby Feytens
- Department
of Organic Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium
| | - Myriam Létourneau
- INRS-Institut
Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Ville de Laval, Québec, QC H7V 1B7, Canada
- Laboratoire International
Associé Samuel de Champlain, INSERM-INRS-Université
de Rouen
| | - Dirk Tourwé
- Department
of Organic Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium
| | - Nicolas Doucet
- INRS-Institut
Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Ville de Laval, Québec, QC H7V 1B7, Canada
- Regroupement
Québécois de Recherche sur la Fonction, la Structure
et l’Ingénierie des Protéines, PROTEO, Québec, QC G1V 0A6, Canada
- GRASP,
Groupe de Recherche Axé sur la Structure des Protéines, McGill University, Bellini Pavillion, Room 453, 3649 Promenade Sir William Osler, Montréal, QC H3G 0B1, Canada
| | - Alain Fournier
- INRS-Institut
Armand-Frappier, Institut national de la recherche scientifique, Université du Québec, Ville de Laval, Québec, QC H7V 1B7, Canada
- Laboratoire International
Associé Samuel de Champlain, INSERM-INRS-Université
de Rouen
| |
Collapse
|
11
|
Martín-Gago P, Aragón E, Gomez-Caminals M, Fernández-Carneado J, Ramón R, Martin-Malpartida P, Verdaguer X, López-Ruiz P, Colás B, Cortes MA, Ponsati B, Macias MJ, Riera A. Insights into structure-activity relationships of somatostatin analogs containing mesitylalanine. Molecules 2013; 18:14564-84. [PMID: 24287991 PMCID: PMC6270305 DOI: 10.3390/molecules181214564] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2013] [Revised: 11/12/2013] [Accepted: 11/13/2013] [Indexed: 12/29/2022] Open
Abstract
The non-natural amino acid mesitylalanine (2,4,6-trimethyl-L-phenylalanine; Msa) has an electron-richer and a more conformationally restricted side-chain than that of its natural phenylalanine counterpart. Taking these properties into account, we have synthesized ten somatostatin analogs containing Msa residues in different key positions to modify the intrinsic conformational flexibility of the natural hormone. We have measured the binding affinity of these analogs and correlated it with the main conformations they populate in solution. NMR and computational analysis revealed that analogs containing one Msa residue were conformationally more restricted than somatostatin under similar experimental conditions. Furthermore, we were able to characterize the presence of a hairpin at the pharmacophore region and a non-covalent interaction between aromatic residues 6 and 11. In all cases, the inclusion of a D-Trp in the eighth position further stabilized the main conformation. Some of these peptides bound selectively to one or two somatostatin receptors with similar or even higher affinity than the natural hormone. However, we also found that multiple incorporations of Msa residues increased the life span of the peptides in serum but with a loss of conformational rigidity and binding affinity.
Collapse
Affiliation(s)
- Pablo Martín-Gago
- Institute for Research in Biomedicine (IRB Barcelona) Baldiri Reixac, 10, Barcelona 08028, Spain; E-Mails: (P.M.-G.); (E.A.); (R.R.); (P.M.-M.); (X.V.)
| | - Eric Aragón
- Institute for Research in Biomedicine (IRB Barcelona) Baldiri Reixac, 10, Barcelona 08028, Spain; E-Mails: (P.M.-G.); (E.A.); (R.R.); (P.M.-M.); (X.V.)
| | - Marc Gomez-Caminals
- BCN Peptides S.A. Pol.Ind. Els Vinyets-Els Fogars, Sector II. Ctra. Comarcal 244, Km. 22, 08777 Sant Quintí de Mediona, Barcelona 08777, Spain; E-Mails: (M.G.-C.); (J.F.-C.); (B.P.)
| | - Jimena Fernández-Carneado
- BCN Peptides S.A. Pol.Ind. Els Vinyets-Els Fogars, Sector II. Ctra. Comarcal 244, Km. 22, 08777 Sant Quintí de Mediona, Barcelona 08777, Spain; E-Mails: (M.G.-C.); (J.F.-C.); (B.P.)
| | - Rosario Ramón
- Institute for Research in Biomedicine (IRB Barcelona) Baldiri Reixac, 10, Barcelona 08028, Spain; E-Mails: (P.M.-G.); (E.A.); (R.R.); (P.M.-M.); (X.V.)
- Departament de Química Orgànica, Universitat de Barcelona, Martí i Franqués, 1-11, Barcelona 08028, Spain
| | - Pau Martin-Malpartida
- Institute for Research in Biomedicine (IRB Barcelona) Baldiri Reixac, 10, Barcelona 08028, Spain; E-Mails: (P.M.-G.); (E.A.); (R.R.); (P.M.-M.); (X.V.)
| | - Xavier Verdaguer
- Institute for Research in Biomedicine (IRB Barcelona) Baldiri Reixac, 10, Barcelona 08028, Spain; E-Mails: (P.M.-G.); (E.A.); (R.R.); (P.M.-M.); (X.V.)
- Departament de Química Orgànica, Universitat de Barcelona, Martí i Franqués, 1-11, Barcelona 08028, Spain
| | - Pilar López-Ruiz
- Departamento de Bioquímica y Biología Molecular, Universidad de Alcalá de Henares, Facultad de Medicina, Madrid 28871, Spain; E-Mails: (P.L.-R.); (B.C.); (M.A.C.)
| | - Begoña Colás
- Departamento de Bioquímica y Biología Molecular, Universidad de Alcalá de Henares, Facultad de Medicina, Madrid 28871, Spain; E-Mails: (P.L.-R.); (B.C.); (M.A.C.)
| | - María Alicia Cortes
- Departamento de Bioquímica y Biología Molecular, Universidad de Alcalá de Henares, Facultad de Medicina, Madrid 28871, Spain; E-Mails: (P.L.-R.); (B.C.); (M.A.C.)
| | - Berta Ponsati
- BCN Peptides S.A. Pol.Ind. Els Vinyets-Els Fogars, Sector II. Ctra. Comarcal 244, Km. 22, 08777 Sant Quintí de Mediona, Barcelona 08777, Spain; E-Mails: (M.G.-C.); (J.F.-C.); (B.P.)
| | - Maria J. Macias
- Institute for Research in Biomedicine (IRB Barcelona) Baldiri Reixac, 10, Barcelona 08028, Spain; E-Mails: (P.M.-G.); (E.A.); (R.R.); (P.M.-M.); (X.V.)
- Institució Catalana de Recerca i Estudis Avançats (ICREA), Passeig Lluis Companys, 23, Barcelona 08010, Spain
- Authors to whom correspondence should be addressed; E-Mails: (M.J.M.); (A.R.); Tel.: +34-934-037-189 (M.J.M.); Fax: +34-934-047-095 (M.J.M.); Tel. +34-934-047-093 (A.R.); Fax: +34-934-047-095 (A.R)
| | - Antoni Riera
- Institute for Research in Biomedicine (IRB Barcelona) Baldiri Reixac, 10, Barcelona 08028, Spain; E-Mails: (P.M.-G.); (E.A.); (R.R.); (P.M.-M.); (X.V.)
- Departament de Química Orgànica, Universitat de Barcelona, Martí i Franqués, 1-11, Barcelona 08028, Spain
- Authors to whom correspondence should be addressed; E-Mails: (M.J.M.); (A.R.); Tel.: +34-934-037-189 (M.J.M.); Fax: +34-934-047-095 (M.J.M.); Tel. +34-934-047-093 (A.R.); Fax: +34-934-047-095 (A.R)
| |
Collapse
|
12
|
Chatenet D, Létourneau M, Nguyen QT, Doan ND, Dupuis J, Fournier A. Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation. Br J Pharmacol 2013; 168:807-21. [PMID: 22994258 DOI: 10.1111/j.1476-5381.2012.02217.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2011] [Revised: 08/15/2012] [Accepted: 08/27/2012] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND AND PURPOSE Recent evidence suggested that urotensin II (UII) and its paralog peptide UII-related peptide (URP) might exert common but also divergent physiological actions. Unfortunately, none of the existing antagonists were designed to discriminate specific UII- or URP-associated actions, and our understanding, on how these two endogenous peptides can trigger different, but also common responses, is limited. EXPERIMENTAL APPROACH Ex vivo rat and monkey aortic ring contraction as well as dissociation kinetics studies using transfected CHO cells expressing the human urotensin (UT) receptors were used in this study. KEY RESULTS Ex vivo rat and monkey aortic ring contraction studies revealed the propensity of [Pep(4)]URP to decrease the maximal response of human UII (hUII) without any significant change in potency, whereas no effect was noticeable on the URP-induced vasoconstriction. Dissociation experiments demonstrated the ability of [Pep(4)]URP to increase the dissociation rate of hUII, but not URP. Surprisingly, URP, an equipotent UII paralog, was also able to accelerate the dissociation rate of membrane-bound (125)I-hUII, whereas hUII had no noticeable effect on URP dissociation kinetics. Further experiments suggested that an interaction between the glutamic residue at position 1 of hUII and the UT receptor seems to be critical to induce conformational changes associated with agonistic activation. Finally, we demonstrated that the N-terminal domain of the rat UII isoform was able to act as a specific antagonist of the URP-associated actions. CONCLUSION Such compounds, that is [Pep(4)]URP and rUII(1-7), should prove to be useful as new pharmacological tools to decipher the specific role of UII and URP in vitro but also in vivo.
Collapse
Affiliation(s)
- D Chatenet
- Laboratoire d'études moléculaires et pharmacologiques des peptides, Université du Québec, INRS-Institut Armand-Frappier, Ville de Laval, QC, Canada.
| | | | | | | | | | | |
Collapse
|
13
|
Stengel A, Rivier J, Taché Y. Modulation of the adaptive response to stress by brain activation of selective somatostatin receptor subtypes. Peptides 2013; 42:70-7. [PMID: 23287111 PMCID: PMC3633742 DOI: 10.1016/j.peptides.2012.12.022] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2012] [Revised: 12/21/2012] [Accepted: 12/21/2012] [Indexed: 01/06/2023]
Abstract
Somatostatin-14 was discovered in 1973 in the hypothalamus as a peptide inhibiting growth hormone release. Somatostatin interacts with five receptor subtypes (sst(1-5)) which are widely distributed in the brain with a distinct, but overlapping, expression pattern. During the last few years, the development of highly selective peptide agonists and antagonists provided new insight to characterize the role of somatostatin receptor subtypes in the pleiotropic actions of somatostatin. Recent evidence in rodents indicates that the activation of selective somatostatin receptor subtypes in the brain blunts stress-corticotropin-releasing factor (CRF) related ACTH release (sst2/5), sympathetic-adrenal activaton (sst5), stimulation of colonic motility (sst1), delayed gastric emptying (sst5), suppression of food intake (sst2) and the anxiogenic-like (sst2) response. These findings suggest that brain somatostatin signaling pathways may play an important role in dampening CRF-mediated endocrine, sympathetic, behavioral and visceral responses to stress.
Collapse
Affiliation(s)
- Andreas Stengel
- CURE: Digestive Diseases Research Center and Center for Neurovisceral Sciences & Women's Health, Digestive Diseases Division, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA
- Division of Psychosomatic Medicine & Obesity Center Berlin, Department of Medicine, Charité Medical Center and University, Berlin, Germany
| | - Jean Rivier
- Peptide Biology Laboratories, Salk Institute, La Jolla, California, USA
| | - Yvette Taché
- CURE: Digestive Diseases Research Center and Center for Neurovisceral Sciences & Women's Health, Digestive Diseases Division, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, California, USA
- Address: CURE: Digestive Diseases Research Center, Building 115, Room 117, VA Greater Los Angeles Healthcare System, 11301 Wilshire Boulevard, Los Angeles, CA 90073, Phone: 310-312-9275, Fax: 1-310-268-4963,
| |
Collapse
|
14
|
Fani M, Braun F, Waser B, Beetschen K, Cescato R, Erchegyi J, Rivier JE, Weber WA, Maecke HR, Reubi JC. Unexpected Sensitivity of sst2 Antagonists to N-Terminal Radiometal Modifications. J Nucl Med 2012; 53:1481-9. [DOI: 10.2967/jnumed.112.102764] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
15
|
Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI Res 2012; 2:25. [PMID: 22682002 PMCID: PMC3407795 DOI: 10.1186/2191-219x-2-25] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2012] [Accepted: 06/09/2012] [Indexed: 02/04/2023] Open
Abstract
Background In this study, we report on the synthesis, radiolabeling, and biological evaluation of two new somatostatin-14 (SS14) analogs, modified with the universal chelator DOTA. We were interested to investigate if and to what extent such radiotracer prototypes may be useful for targeting sst1-5-expressing tumors in man but, most importantly, to outline potential drawbacks and benefits associated with their use. Methods AT1S and AT2S (DOTA-Ala1-Gly2-c[Cys3-Lys4-Asn5-Phe6-Phe7-Trp8/DTrp8-Lys9-Thr10-Phe11-Thr12-Ser13-Cys14-OH], respectively) were synthesized on the solid support and labeled with 111In. The sst1-5 affinity profile of AT1S/AT2S was determined by receptor autoradiography using [Leu8,dTrp22,125I-Tyr25]SS28 as radioligand. The ability of AT2S to stimulate sst2 or sst3 internalization was qualitatively analyzed by an immunofluorescence-based internalization assay using hsst2- or hsst3-expressing HEK293 cells. Furthermore, the internalization of the radioligands [111In]AT1S and [111In]AT2S was studied at 37 °C in AR4-2J cells endogenously expressing sst2. The in vivo stability of [111In]AT1S and [111In]AT2S was tested by high-performance liquid chromatography analysis of mouse blood collected 5 min after radioligand injection, and biodistribution was studied in normal mice. Selectively for [111In]AT2S, biodistribution was further studied in SCID mice bearing AR4-2J, HEK293-hsst2A+, -hsst3+ or -hsst5+ tumors. Results The new SS14-derived analogs were obtained by solid phase peptide synthesis and were easily labeled with 111In. Both SS14 conjugates, AT1S, and its DTrp8 counterpart, AT2S, showed a pansomatostatin affinity profile with the respective hsst1-5 IC50 values in the lower nanomolar range. In addition, AT2S behaved as an agonist for sst2 and sst3 since it stimulated receptor internalization. The 111In radioligands effectively and specifically internalized into rsst2A-expressing AR4-2J cells with [111In]AT2S internalizing faster than [111In]AT1S. Ex vivo mouse blood analysis revealed a rapid degradation of both radiopeptides in the bloodstream with the DTrp8 analog showing higher stability. Biodistribution results in healthy mice were consistent with these findings with only [111In]AT2S showing specific uptake in the sst2-rich pancreas. Biodistribution of [111In]AT2S in tumor-bearing mice revealed receptor-mediated uptake in the AR4-2J (1.82 ± 0.36 %ID/g - block 0.21 ± 0.17 %ID/g at 4 h post injection (pi)), the HEK293-hsst2A+ (1.49 ± 0.2 %ID/g - block 0.27 ± 0.20 %ID/g at 4 h pi), the HEK293-hsst3+ (1.24 ± 0.27 %ID/g - block 0.32 ± 0.06 %ID/g at 4 h pi), and the HEK293-hsst5+ tumors (0.41 ± 0.12 %ID/g - block 0.22 ± 0.006 %ID/g at 4 h pi). Radioactivity washed out from blood and background tissues via the kidneys. Conclusions This study has revealed that the native SS14 structure can indeed serve as a motif for the development of promising pansomatostatin-like radiotracers. Further peptide stabilization is required to increase in vivo stability and, consequently, to enhance in vivo delivery and tumor targeting.
Collapse
Affiliation(s)
- Aikaterini Tatsi
- Molecular Radiopharmacy, Institute of Radioisotopes - Radiodiagnostic Products, National Center for Scientific Research "Demokritos", 153 10 Ag, Paraskevi Attikis, Athens, GR-153 10, Greece.
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Chatenet D, Nguyen QT, Létourneau M, Dupuis J, Fournier A. Urocontrin, a novel UT receptor ligand with a unique pharmacological profile. Biochem Pharmacol 2012; 83:608-15. [DOI: 10.1016/j.bcp.2011.12.009] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2011] [Revised: 12/05/2011] [Accepted: 12/08/2011] [Indexed: 01/23/2023]
|
17
|
Stengel A, Taché Y. Activation of somatostatin 2 receptors in the brain and the periphery induces opposite changes in circulating ghrelin levels: functional implications. Front Endocrinol (Lausanne) 2012; 3:178. [PMID: 23335913 PMCID: PMC3542632 DOI: 10.3389/fendo.2012.00178] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2012] [Accepted: 12/17/2012] [Indexed: 12/26/2022] Open
Abstract
Somatostatin is an important modulator of neurotransmission in the central nervous system and acts as a potent inhibitor of hormone and exocrine secretion and regulator of cell proliferation in the periphery. These pleiotropic actions occur through interaction with five G protein-coupled somatostatin receptor subtypes (sst(1) (-) (5)) that are widely expressed in the brain and peripheral organs. The characterization of somatostatin's effects can be investigated by pharmacological or genetic approaches using newly developed selective sst agonists and antagonists and mice lacking specific sst subtypes. Recent evidence points toward a divergent action of somatostatin in the brain and in the periphery to regulate circulating levels of ghrelin, an orexigenic hormone produced by the endocrine X/A-like cells in the rat gastric mucosa. Somatostatin interacts with the sst(2) in the brain to induce an increase in basal ghrelin plasma levels and counteracts the visceral stress-related decrease in circulating ghrelin. By contrast, stimulation of peripheral somatostatin-sst(2) signaling results in the inhibition of basal ghrelin release and mediates the postoperative decrease in circulating ghrelin. The peripheral sst(2)-mediated reduction of plasma ghrelin is likely to involve a paracrine action of D cell-derived somatostatin acting on sst(2) bearing X/A-like ghrelin cells in the gastric mucosa. The other member of the somatostatin family, named cortistatin, in addition to binding to sst(1) (-) (5) also directly interacts with the ghrelin receptor and therefore may simultaneously modulate ghrelin release and actions at target sites bearing ghrelin receptors representing a link between the ghrelin and somatostatin systems.
Collapse
Affiliation(s)
- Andreas Stengel
- Division Psychosomatic Medicine and Psychotherapy, Department of Medicine, Obesity Center Berlin, Charité, Universitätsmedizin BerlinBerlin, Germany
- *Correspondence: Andreas Stengel, Division Psychosomatic Medicine and Psychotherapy, Department of Medicine, Obesity Center Berlin, Charité, Universitätsmedizin Berlin, Luisenstr. 13a, 10117 Berlin, Germany. e-mail: ; Yvette Taché, Digestive Diseases Division, CURE: Digestive Diseases Research Center, Center for Neurobiology of Stress and Women’s Health, Department of Medicine, VA Greater Los Angeles Health Care System, University of California at Los Angeles, CURE Building 115, Room 117, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA. e-mail:
| | - Yvette Taché
- Digestive Diseases Division, CURE: Digestive Diseases Research Center, Center for Neurobiology of Stress and Women’s Health, Department of Medicine, VA Greater Los Angeles Health Care System, University of California at Los AngelesLos Angeles, CA, USA
- *Correspondence: Andreas Stengel, Division Psychosomatic Medicine and Psychotherapy, Department of Medicine, Obesity Center Berlin, Charité, Universitätsmedizin Berlin, Luisenstr. 13a, 10117 Berlin, Germany. e-mail: ; Yvette Taché, Digestive Diseases Division, CURE: Digestive Diseases Research Center, Center for Neurobiology of Stress and Women’s Health, Department of Medicine, VA Greater Los Angeles Health Care System, University of California at Los Angeles, CURE Building 115, Room 117, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA. e-mail:
| |
Collapse
|
18
|
Martín-Gago P, Gomez-Caminals M, Ramón R, Verdaguer X, Martin-Malpartida P, Aragón E, Fernández-Carneado J, Ponsati B, López-Ruiz P, Cortes MA, Colás B, Macias MJ, Riera A. Fine-tuning the π-π Aromatic Interactions in Peptides: Somatostatin Analogues Containing Mesityl Alanine. Angew Chem Int Ed Engl 2011. [DOI: 10.1002/ange.201106406] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
19
|
Martín-Gago P, Gomez-Caminals M, Ramón R, Verdaguer X, Martin-Malpartida P, Aragón E, Fernández-Carneado J, Ponsati B, López-Ruiz P, Cortes MA, Colás B, Macias MJ, Riera A. Fine-tuning the π-π Aromatic Interactions in Peptides: Somatostatin Analogues Containing Mesityl Alanine. Angew Chem Int Ed Engl 2011; 51:1820-5. [DOI: 10.1002/anie.201106406] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2011] [Indexed: 01/04/2023]
|
20
|
Cescato R, Waser B, Fani M, Reubi JC. Evaluation of 177Lu-DOTA-sst2 Antagonist Versus 177Lu-DOTA-sst2 Agonist Binding in Human Cancers In Vitro. J Nucl Med 2011; 52:1886-90. [DOI: 10.2967/jnumed.111.095778] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
21
|
Chatenet D, Cescato R, Waser B, Erchegyi J, Rivier JE, Reubi JC. Novel dimeric DOTA-coupled peptidic Y1-receptor antagonists for targeting of neuropeptide Y receptor-expressing cancers. EJNMMI Res 2011; 1:21. [PMID: 22214201 PMCID: PMC3250963 DOI: 10.1186/2191-219x-1-21] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2011] [Accepted: 09/02/2011] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Several peptide hormone receptors were identified that are specifically over-expressed on the cell surface of certain human tumors. For example, high incidence and density of the Y1 subtype of neuropeptide Y (NPY) receptors are found in breast tumors. Recently, we demonstrated that the use of potent radiolabeled somatostatin or bombesin receptor antagonists considerably improved the sensitivity of in vivo imaging when compared to agonists. We report here on the first DOTA-coupled peptidic Y1 receptor affine dimer antagonists. METHODS Based on a Y1 affine dimeric peptide scaffold previously reported to competitively antagonize NPY-mediated processes, we have developed new dimeric DOTA-coupled Y1 receptor affine antagonists for scintigraphy and radiotherapy. These dimeric peptides were tested for their specific binding to Y1 expressed in SK-N-MC cells and Y2 expressed in SH-SY5Y as well as for their ability to mediate cAMP production in SK-N-MC cells. RESULTS Introduction of two DOTA moieties at the N-termini of the dimeric NPY analogs as well as the double Asn29 replacement by Dpr(DOTA) or Lys(DOTA) (6 and 10) moiety dramatically reduced binding affinity. However, asymmetric introduction of the DOTA moiety in one segment of the peptidic heterodimer (8 and 11) resulted in suitable antagonists for receptor targeting with high binding affinity for Y1. All compounds were devoid of Y2 binding affinity. CONCLUSIONS The design and the in vitro characterization of the first DOTA-coupled dimeric NPY receptor antagonist with high affinity and selectivity for Y1 over Y2 are described. This compound may be an excellent candidate for the imaging of Y1-positive tumors and their treatment.
Collapse
Affiliation(s)
- David Chatenet
- The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, 10010 N, Torrey Pines Rd,, La Jolla, CA, USA.
| | | | | | | | | | | |
Collapse
|
22
|
Erchegyi J, Cescato R, Waser B, Rivier JE, Reubi JC. N-imidazolebenzyl-histidine substitution in somatostatin and in its octapeptide analogue modulates receptor selectivity and function. J Med Chem 2011; 54:5981-7. [PMID: 21806016 DOI: 10.1021/jm200307v] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Despite 3 decades of focused chemical, biological, structural, and clinical developments, unusual properties of somatostatin (SRIF, 1) analogues are still being uncovered. Here we report the unexpected functional properties of 1 and the octapeptide cyclo(3-14)H-Cys-Phe-Phe-Trp(8)-Lys-Thr-Phe-Cys-OH (somatostatin numbering; OLT-8, 9) substituted by imBzl-l- or -d-His at position 8. These analogues were tested for their binding affinity to the five human somatostatin receptors (sst(1-5)), as well as for their functional properties (or functionalities) in an sst(3) internalization assay and in an sst(3) luciferase reporter gene assay. While substitution of Trp(8) in somatostatin by imBzl-l- or -d-His(8) results in sst(3) selectivity, substitution of Trp(8) in the octapeptide 9 by imBzl-l- or -d-His(8) results in loss of binding affinity for sst(1,2,4,5) and a radical functional switch from agonist to antagonist.
Collapse
Affiliation(s)
- Judit Erchegyi
- The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, 10010 N. Torrey Pines Road, La Jolla, California 92037, USA
| | | | | | | | | |
Collapse
|
23
|
STENGEL A, GOEBEL-STENGEL M, WANG L, LUCKEY A, HU E, RIVIER J, TACHÉ Y. Central administration of pan-somatostatin agonist ODT8-SST prevents abdominal surgery-induced inhibition of circulating ghrelin, food intake and gastric emptying in rats. Neurogastroenterol Motil 2011; 23:e294-308. [PMID: 21569179 PMCID: PMC3117963 DOI: 10.1111/j.1365-2982.2011.01721.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Activation of brain somatostatin receptors (sst(1-5) ) with the stable pan-sst(1-5) somatostatin agonist, ODT8-SST blocks acute stress and central corticotropin-releasing factor (CRF)-mediated activation of endocrine and adrenal sympathetic responses. Brain CRF signaling is involved in delaying gastric emptying (GE) immediately post surgery. We investigated whether activation of brain sst signaling pathways modulates surgical stress-induced inhibition of gastric emptying and food intake. METHODS Fasted rats were injected intracisternally (i.c.) with somatostatin agonists and underwent laparotomy and 1-min cecal palpation. Gastric emptying of a non-nutrient solution and circulating acyl and desacyl ghrelin levels were assessed 50min post surgery. Food intake was monitored for 24 h. KEY RESULTS The abdominal surgery-induced inhibition of GE (65%), food intake (73% at 2h) and plasma acyl ghrelin levels (67%) was completely prevented by ODT8-SST (1μg per rat, i.c.). The selective sst(5) agonist, BIM-23052 prevented surgery-induced delayed GE, whereas selective sst(1) , sst(2) , or sst(4) agonists had no effect. However, the selective sst(2) agonist, S-346-011 (1μg per rat, i.c.) counteracted the abdominal surgery-induced inhibition of acyl ghrelin and food intake but not the delayed GE. The ghrelin receptor antagonist, [D-Lys(3) ]-GHRP-6 (0.93mg kg(-1) , intraperitoneal, i.p.) blocked i.p. ghrelin-induced increased GE, while not influencing i.c. ODT8-SST-induced prevention of delayed GE and reduced food intake after surgery. CONCLUSIONS & INFERENCES ODT8-SST acts in the brain to prevent surgery-induced delayed GE likely via activating sst(5) . ODT8-SST and the sst(2) agonist prevent the abdominal surgery-induced decrease in food intake and plasma acyl ghrelin indicating dissociation between brain somatostatin signaling involved in preventing surgery-induced suppression of GE and feeding response.
Collapse
Affiliation(s)
- A. STENGEL
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| | - M. GOEBEL-STENGEL
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| | - L. WANG
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| | - A. LUCKEY
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| | - E. HU
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| | - J. RIVIER
- Peptide Biology Laboratories, Salk Institute, La Jolla, CA, USA
| | - Y. TACHÉ
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| |
Collapse
|
24
|
STENGEL A, GOEBEL-STENGEL M, WANG L, LARAUCHE M, RIVIER J, TACHÉ Y. Central somatostatin receptor 1 activation reverses acute stress-related alterations of gastric and colonic motor function in mice. Neurogastroenterol Motil 2011; 23:e223-36. [PMID: 21564422 PMCID: PMC3683311 DOI: 10.1111/j.1365-2982.2011.01706.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Corticotropin-releasing factor (CRF) signaling induced by stress is well established to delay gastric emptying (GE) and stimulate colonic functions. The somatostatin receptor (sst(1-5) ) agonist, ODT8-SST acts in the brain to inhibit stress-induced adrenocorticotropic hormone and epinephrine secretion. We investigated whether ODT8-SST acts in the brain to influence stress-related alterations of gastric and colonic motor function and sst receptor subtype(s) involved. METHODS Peptides were injected intracerebroventricularly (i.c.v.) under short isoflurane anesthesia and GE, fecal pellet output (FPO) and distal colonic motility monitored in conscious mice. KEY RESULTS The stress of acute anesthesia/vehicle i.c.v. injection reduced GE by 67% and increased defecation by 99% compared to non-injected controls. Both responses were abolished by ODT8-SST (1μg= 0.75nmol) or sst(1) agonist (0.65-1.95nmol). The sst(1) agonist (1.95nmol) also prevented the abdominal surgery-induced delayed GE. Octreotide (sst(2) >sst(5) > sst(3) ) and the sst(2) or sst(4) agonists (1μg=0.78 or 0.70nmol, respectively) injected i.c.v. did not influence FPO while i.c.v. somatostatin-28 mimicked ODT8-SST's effect. The ODT8-SST-induced increased food intake was inhibited by i.c.v. sst(2) antagonist while the reduced FPO was unchanged. ODT8-SST i.c.v. reduced distal colonic motility in semi-restrained mice compared with vehicle and blocked water avoidance- and i.c.v. CRF (0.5μg=0.09nmol)-induced stimulated FPO while a similar colonic secretomotor response to i.p. 5-hydroxytryptophane (10mgkg(-1) =36.4μmol kg(-1) ) was unaltered. Conclusions & Inferences ODT8-SST counteracts stress/i.c.v. CRF-related stimulation of colonic motor function and delayed GE which can be reproduced mainly by activation of sst(1) receptors. These data opens new insight to brain somatostatinergic signaling pathways interfering with brain circuitries involved in gut motor responses to acute stress.
Collapse
Affiliation(s)
- A. STENGEL
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| | - M. GOEBEL-STENGEL
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| | - L. WANG
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| | - M. LARAUCHE
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| | - J. RIVIER
- Peptide Biology Laboratories, Salk Institute, La Jolla, CA, USA
| | - Y. TACHÉ
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and VA Greater Los Angeles Health Care System, CA 90073, USA
| |
Collapse
|
25
|
Kolenc-Peitl P, Mansi R, Tamma M, Gmeiner-Stopar T, Sollner-Dolenc M, Waser B, Baum RP, Reubi JC, Maecke HR. Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. J Med Chem 2011; 54:2602-9. [PMID: 21456601 DOI: 10.1021/jm101279a] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The development of metabolically stable radiolabeled gastrin analogues with suitable pharmacokinetics is a topic of recent research activity. These imaging vectors are of interest because the gastrin/CCK2 receptor is highly overexpressed in different tumors such as medullary thyroid cancer, neuroendocrine tumors, and SCLC. The drawback of current targeting agents is either their metabolic instability or their high kidney uptake. We present the synthesis and in vitro and in vivo evaluation of 11 (111)In-labeled DOTA-conjugated peptides that differ by their spacer between the peptide and the chelate. We introduced uncharged but hydrophilic spacers such as oligoethyleneglycol, serine, and glutamine. The affinity of all radiopeptides was high with IC(50) values between 0.5 and 4.8 nM. The improvement of human serum stability is 500-fold within this series of compounds. In addition the kidney uptake could be lowered distinctly and the tumor-to-kidney ratio improved almost 60-fold if compared with radiotracers having charged spacers such as glutamic acid.
Collapse
Affiliation(s)
- Petra Kolenc-Peitl
- Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Robertson CR, Flynn SP, White HS, Bulaj G. Anticonvulsant neuropeptides as drug leads for neurological diseases. Nat Prod Rep 2011; 28:741-62. [PMID: 21340067 DOI: 10.1039/c0np00048e] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Anticonvulsant neuropeptides are best known for their ability to suppress seizures and modulate pain pathways. Galanin, neuropeptide Y, somatostatin, neurotensin, dynorphin, among others, have been validated as potential first-in-class anti-epileptic or/and analgesic compounds in animal models of epilepsy and pain, but their therapeutic potential extends to other neurological indications, including neurodegenerative and psychatric disorders. Disease-modifying properties of neuropeptides make them even more attractive templates for developing new-generation neurotherapeutics. Arguably, efforts to transform this class of neuropeptides into drugs have been limited compared to those for other bioactive peptides. Key challenges in developing neuropeptide-based anticonvulsants are: to engineer optimal receptor-subtype selectivity, to improve metabolic stability and to enhance their bioavailability, including penetration across the blood–brain barrier (BBB). Here, we summarize advances toward developing systemically active and CNS-penetrant neuropeptide analogs. Two main objectives of this review are: (1) to provide an overview of structural and pharmacological properties for selected anticonvulsant neuropeptides and their analogs and (2) to encourage broader efforts to convert these endogenous natural products into drug leads for pain, epilepsy and other neurological diseases.
Collapse
Affiliation(s)
- Charles R Robertson
- College of Pharmacy, Department of Medicinal Chemistry, 421 Wakara Way, STE. 360 Salt Lake City, UT 84108, USA
| | | | | | | |
Collapse
|
27
|
Wängler C, Waser B, Alke A, Iovkova L, Buchholz HG, Niedermoser S, Jurkschat K, Fottner C, Bartenstein P, Schirrmacher R, Reubi JC, Wester HJ, Wängler B. One-Step 18F-Labeling of Carbohydrate-Conjugated Octreotate-Derivatives Containing a Silicon-Fluoride-Acceptor (SiFA): In Vitro and in Vivo Evaluation as Tumor Imaging Agents for Positron Emission Tomography (PET). Bioconjug Chem 2010; 21:2289-96. [DOI: 10.1021/bc100316c] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
- Carmen Wängler
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Beatrice Waser
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Andrea Alke
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Ljuba Iovkova
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Hans-Georg Buchholz
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Sabrina Niedermoser
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Klaus Jurkschat
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Christian Fottner
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Peter Bartenstein
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Ralf Schirrmacher
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Jean-Claude Reubi
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Hans-Jürgen Wester
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| | - Björn Wängler
- Department of Nuclear Medicine, Hospital of the Ludwig-Maximilians-University, Munich, Germany, Institute of Pathology, University of Berne, Berne, Switzerland, Department of Nuclear Medicine, Technical University Munich, Munich, Germany, Department of Inorganic Chemistry II, University of Dortmund, Dortmund, Germany, Department of Nuclear Medicine and I. Medical Clinic, University of Mainz, Germany, and McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada
| |
Collapse
|
28
|
Waser B, Cescato R, Tamma ML, Maecke HR, Reubi JC. Absence of somatostatin SST2 receptor internalization in vivo after intravenous SOM230 application in the AR42J animal tumor model. Eur J Pharmacol 2010; 644:257-62. [DOI: 10.1016/j.ejphar.2010.07.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2010] [Revised: 07/01/2010] [Accepted: 07/09/2010] [Indexed: 12/19/2022]
|
29
|
Stengel A, Goebel M, Wang L, Rivier J, Kobelt P, Mönnikes H, Taché Y. Activation of brain somatostatin 2 receptors stimulates feeding in mice: analysis of food intake microstructure. Physiol Behav 2010; 101:614-22. [PMID: 20851136 DOI: 10.1016/j.physbeh.2010.09.009] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2010] [Revised: 09/04/2010] [Accepted: 09/13/2010] [Indexed: 01/23/2023]
Abstract
We recently reported that the oligosomatostatin receptor agonist, ODT8-SST increases food intake in rats via the somatostatin 2 receptor (sst(2)). We characterized ingestive behavior following intracerebroventricular (icv) injection of a selective sst(2) agonist in freely fed mice during the light phase. The sst(2) agonist (0.01, 0.03, 0.1, 0.3 or 1μg/mouse) injected icv under short inhalation anesthesia dose-dependently increased cumulative light phase food intake over 4h compared to vehicle with a 3.1-times increase at 1μg/mouse (p<0.05). Likewise, the sst(2,3,5) agonist octreotide (0.3 or 1μg/mouse) dose-dependently increased 4-h food intake, whereas selective sst(1) or sst(4) agonists at 1μg/mouse did not. In vehicle-treated mice, high fat diet increased caloric intake/4h by 2.8-times compared to regular diet (p<0.05) and values were further increased 1.4-times/4h by the sst(2) agonist. Automated continuous assessment of food intake established a 6.6-times higher food intake during the dark phase due to increased number of meals, meal size, meal duration and rate of ingestion compared to non-treated mice during the light phase. During the first 4h post icv sst(2) agonist injection, mice had a 57% increase in number of meals with a 60% higher rate of ingestion, and a 61% reduction in inter-meal intervals, whereas meal sizes were not altered compared to vehicle. These data indicate that the activation of brain sst(2) receptors potently stimulates the light phase ingestive behavior under basal or high fat diet-stimulated conditions in mice. The shortened inter-meal interval suggests an inhibitory effect of the sst(2) agonist on "satiety", whereas "satiation" is not altered as indicated by normal meal size.
Collapse
Affiliation(s)
- Andreas Stengel
- CURE/Digestive Diseases Research Center, Center for Neurobiology of Stress, Department of Medicine, Digestive Diseases Division at the University of California Los Angeles, and Veterans Affairs Greater Los Angeles Health Care System, CA 90073, USA
| | | | | | | | | | | | | |
Collapse
|
30
|
Stengel A, Coskun T, Goebel M, Wang L, Craft L, Alsina-Fernandez J, Rivier J, Taché Y. Central injection of the stable somatostatin analog ODT8-SST induces a somatostatin2 receptor-mediated orexigenic effect: role of neuropeptide Y and opioid signaling pathways in rats. Endocrinology 2010; 151:4224-35. [PMID: 20610566 PMCID: PMC2940496 DOI: 10.1210/en.2010-0195] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Somatostatin and octreotide injected into the brain have been reported to modulate food intake. However, little is known regarding the underlying mechanisms. The stable oligosomatostatin analog, des-AA(1,2,4,5,12,13)-[DTrp(8)]-somatostatin (ODT8-SST), like somatostatin, binds to all five somatostatin receptors (sst(1-5)). We characterized the effects of ODT8-SST injected intracerebroventricularly (i.c.v.) on food consumption and related mechanisms of action in freely fed rats. ODT8-SST (0.3 and 1 microg per rat, i.c.v.) injected during the light or dark phase induced an early onset (within 1 h) and long-lasting (4 h) increase in food intake in nonfasted rats. By contrast, i.p. injection (0.3-3 mg/kg) or i.c.v. injection of selective sst(1) or sst(4) agonists (1 microg per rat) had no effect. The 2 h food intake response during the light phase was blocked by i.c.v. injection of a sst(2) antagonist, the neuropeptide Y (NPY) Y(1) receptor antagonist, BIBP-3226, and ip injection of the mu-opioid receptor antagonist, naloxone, and not associated with changes in plasma ghrelin levels. ODT8-SST (1 microg per rat, i.c.v.) stimulated gastric emptying of a solid meal which was also blocked by naloxone. The increased food intake was accompanied by a sustained increase in respiratory quotient, energy expenditure, and drinking as well as mu-opioid receptor-independent grooming behavior and hyperthermia, while ambulatory movements were not altered after ODT8-SST (1 microg per rat, i.c.v.). These data show that ODT8-SST acts primarily through brain sst(2) receptors to induce a long-lasting orexigenic effect that involves the activation of Y(1) and opiate-receptors, accompanied by enhanced gastric transit and energy expenditure suggesting a modulation of NPYergic and opioidergic orexigenic systems by brain sst(2) receptors.
Collapse
MESH Headings
- Animals
- Anti-Anxiety Agents/administration & dosage
- Anti-Anxiety Agents/pharmacology
- Arginine/administration & dosage
- Arginine/analogs & derivatives
- Arginine/pharmacology
- Body Temperature/drug effects
- Eating/drug effects
- Eating/physiology
- Energy Metabolism/drug effects
- Gastric Emptying/drug effects
- Grooming/drug effects
- Injections, Intraperitoneal
- Injections, Intraventricular
- Male
- Mice
- Mice, Inbred C57BL
- Naloxone/administration & dosage
- Naloxone/pharmacology
- Peptide Fragments/administration & dosage
- Peptide Fragments/pharmacology
- Rats
- Rats, Sprague-Dawley
- Receptors, Neuropeptide Y/antagonists & inhibitors
- Receptors, Neuropeptide Y/physiology
- Receptors, Opioid, mu/antagonists & inhibitors
- Receptors, Opioid, mu/physiology
- Receptors, Somatostatin/agonists
- Receptors, Somatostatin/antagonists & inhibitors
- Receptors, Somatostatin/physiology
- Somatostatin/administration & dosage
- Somatostatin/analogs & derivatives
- Somatostatin/pharmacology
Collapse
Affiliation(s)
- Andreas Stengel
- Department of Medicine, Center for Ulcer Research and Education, Digestive Diseases Division, University of California Los Angeles, and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California 90073, USA
| | | | | | | | | | | | | | | |
Collapse
|
31
|
Di Cianni A, Carotenuto A, Brancaccio D, Novellino E, Reubi JC, Beetschen K, Papini AM, Ginanneschi M. Novel Octreotide Dicarba-analogues with High Affinity and Different Selectivity for Somatostatin Receptors. J Med Chem 2010; 53:6188-97. [DOI: 10.1021/jm1005868] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Affiliation(s)
- Alessandra Di Cianni
- Laboratory of Peptides & Proteins, Chemistry & Biology, University of Firenze, Via della Lastruccia 13, I-50019 Sesto Fiorentino, Italy
- Department of Chemistry “Ugo Schiff”, University of Firenze, Via della Lastruccia 5-13, I-50019, Sesto Fiorentino, Italy
| | - Alfonso Carotenuto
- Department of Pharmaceutical Chemistry and Toxicology, University of Napoli, Via Domenico Montesano 49, I-80131 Napoli, Italy
| | - Diego Brancaccio
- Department of Pharmaceutical Chemistry and Toxicology, University of Napoli, Via Domenico Montesano 49, I-80131 Napoli, Italy
| | - Ettore Novellino
- Department of Pharmaceutical Chemistry and Toxicology, University of Napoli, Via Domenico Montesano 49, I-80131 Napoli, Italy
| | - Jean Claude Reubi
- Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Murtenstrasse 31, CH-3010 Berne, Switzerland
| | - Karin Beetschen
- Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Murtenstrasse 31, CH-3010 Berne, Switzerland
| | - Anna Maria Papini
- Laboratory of Peptides & Proteins, Chemistry & Biology, University of Firenze, Via della Lastruccia 13, I-50019 Sesto Fiorentino, Italy
- Department of Chemistry “Ugo Schiff”, University of Firenze, Via della Lastruccia 5-13, I-50019, Sesto Fiorentino, Italy
| | - Mauro Ginanneschi
- Laboratory of Peptides & Proteins, Chemistry & Biology, University of Firenze, Via della Lastruccia 13, I-50019 Sesto Fiorentino, Italy
- Department of Chemistry “Ugo Schiff”, University of Firenze, Via della Lastruccia 5-13, I-50019, Sesto Fiorentino, Italy
| |
Collapse
|
32
|
Ovadia O, Greenberg S, Laufer B, Gilon C, Hoffman A, Kessler H. Improvement of drug-like properties of peptides: the somatostatin paradigm. Expert Opin Drug Discov 2010; 5:655-71. [DOI: 10.1517/17460441.2010.493935] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
33
|
Reubi JC, Erchegyi J, Cescato R, Waser B, Rivier JE. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog. Eur J Nucl Med Mol Imaging 2010; 37:1551-8. [PMID: 20396884 DOI: 10.1007/s00259-010-1445-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2009] [Accepted: 03/08/2010] [Indexed: 12/13/2022]
Abstract
PURPOSE Peptide receptor targeting has become an increasingly attractive method to target tumors diagnostically and radiotherapeutically. Peptides linked to a variety of chelators have been developed for this purpose. They have, however, rarely been tested for their agonistic or antagonistic properties. We report here on a somatostatin antagonist that switched to an agonist upon coupling to a DOTA chelator. METHODS Two novel somatostatin analogs, 406-040-15 and its DOTA-coupled counterpart 406-051-20, with and without cold Indium labeling, were tested for their somatostatin receptor subtypes 1-5 (sst(1)-sst(5)) binding affinity using receptor autoradiography. Moreover, they were tested functionally for their ability to affect sst(2) and sst(3) internalization in vitro in HEK293 cells stably expressing the human sst(2) or sst(3) receptor, using an immunofluorescence microscopy-based internalization assay. RESULTS All three compounds were characterized as pan-somatostatin analogs having a high affinity for all five sst. In the sst(2) internalization assay, all three compounds showed an identical behavior, namely, a weak agonistic effect complemented by a weak antagonistic effect, compatible with the behavior of a partial agonist. Conversely, in the sst(3) internalization assay, 406-040-15 was a full antagonist whereas its DOTA-coupled counterpart, 406-051-20, with and without Indium labeling, switched to a full agonist. CONCLUSION Adding the DOTA chelator to the somatostatin analog 406-040-15 triggers a switch at sst(3) receptor from an antagonist to an agonist. This indicates that potential radioligands for tumor targeting should always be tested functionally before further development, in particular if a chelator is added.
Collapse
Affiliation(s)
- Jean Claude Reubi
- Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, PO Box 62, Murtenstrasse 31, 3010 Berne, Switzerland.
| | | | | | | | | |
Collapse
|